Neurolixis has initiated a Phase 2a clinical trial evaluating NLX-112 in Parkinson's disease patients with disabling levodopa-induced dyskinesia (LID). Levodopa is the main pharmacotherapeutic treatment for Parkinson's disease, but it can cause involuntary movements, called dyskinesia, after several years of treatment. NLX-112 acts on the brain's serotonin system and is a highly specific and effective activator of neuronal proteins known as 5-HT1A receptors. Neurolixis has previously demonstrated that NLX-112 exhibits strong anti-dyskinetic activity in preclinical models of Parkinson's disease, without interfering with the therapeutic properties of Levodopa. NLX-112 is administered orally and has already been safely evaluated in over 600 human subjects.

The clinical study, registered on the database and conducted at five sites in Sweden, will enroll a total of 24 patients in a double-blind, placebo-controlled, randomized trial. The major research foundations Parkinson UK and the Michael J. Fox Foundation for Parkinson's Research (MJFF) have partnered with Neurolixis to fund the study.

See the full press release.


Please enable the javascript to submit this form

Follow Neurolixis on: